Insider Selling: Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells 2,000 Shares of Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 2,000 shares of the business’s stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $12.27, for a total transaction of $24,540.00. Following the completion of the sale, the president now owns 2,932,467 shares in the company, valued at approximately $35,981,370.09. This trade represents a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Songjiang Ma also recently made the following trade(s):

• On Thursday, December 19th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.82, for a total value of $21,640.00.
• On Tuesday, December 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.05, for a total value of $22,100.00.

Gyre Therapeutics Price Performance

NASDAQ GYRE opened at $12.45 on Friday. The business’s 50 day moving average price is $12.71 and its 200-day moving average price is $12.63. Gyre Therapeutics, Inc. has a fifty-two week low of $8.26 and a fifty-two week high of $27.45.

Institutional Trading of Gyre Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of New York Mellon Corp bought a new stake in Gyre Therapeutics during the 2nd quarter valued at about $218,000. Rhumbline Advisers purchased a new position in shares of Gyre Therapeutics during the second quarter worth approximately $123,000. WINTON GROUP Ltd bought a new stake in shares of Gyre Therapeutics during the second quarter valued at approximately $220,000. Renaissance Technologies LLC purchased a new position in Gyre Therapeutics during the 2nd quarter worth $166,000. Finally, Charles Schwab Investment Management Inc. raised its position in Gyre Therapeutics by 392.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock valued at $1,425,000 after purchasing an additional 90,557 shares in the last quarter. Hedge funds and other institutional investors own 23.99% of the company’s stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.